Abstract
Human haemorrhoidal disease (HEM) is a common anorectal pathology. Being one of the diseases that affect a wide range of people, the etiology of HEM, as well as its molecular mechanism, remains largely unclear. In this study, we applied a two-sample bi-direction Mendelian randomization (MR) analysis to estimate the causal effects of 4677 plasma proteins on HEM outcomes and investigated the mediating impacts of plasma proteins on HEM risk factors to uncover potential HEM treatment targets by integrating GWASs statistics of HEM and plasma protein levels. Following MR analysis, our study identified 13 probable causal proteins associated with HEM. Particularly, genetically predicted OLFM1 levels were linked to an increased risk of HEM. In addition, it was discovered that a genetically greater risk of myxoedema, diverticular disease, and ulcerative colitis was linked to an elevated risk of HEM (FDR<0.05). However, there was no evidence that dorsalgia, hernia, and ankylosing spondylitis were causally associated with HEM. Interestingly, a higher risk of myxoedema was associated with higher genetically predicted OLFM1 levels. Finally, mediation analysis suggested that the effect of myxoedema on HEM via OLFM1 might explain 32.8% of the mediation effect. Overall, this study identified some causal associations of circulating proteins and risk factors with HEM by integrating the largest-to-date plasma proteome and GWASs of HEM. The findings could provide further insight into understanding biological mechanisms for HEM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SF and MJ are the fellow of the Chinese Scholarship Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
